{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:18Z","timestamp":1793915298675,"version":"4.8.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10\u201320% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes. Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating and managing patients undergoing radioembolization treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Preamble<\/jats:title>\n                    <jats:p>The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not\ninflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine involves not only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to\npredict with certainty a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-021-05600-z","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T23:29:58Z","timestamp":1644535798000},"page":"1682-1699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":251,"title":["EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds"],"prefix":"10.1007","volume":"49","author":[{"given":"M.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cremonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gnesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kracmerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"issue":"9","key":"5600_CR1","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467\u201375.","journal-title":"J Nucl Med"},{"issue":"8","key":"5600_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with (90)yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251\u201378.","journal-title":"J Vasc Interv Radiol"},{"key":"5600_CR3","doi-asserted-by":"crossref","unstructured":"Smits MLJ, et al., Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental & Clinical Cancer Research, 2010. 29.","DOI":"10.1186\/1756-9966-29-70"},{"issue":"4","key":"5600_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","volume":"1","author":"MA Westcott","year":"2016","unstructured":"Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351\u201364.","journal-title":"Adv Radiat Oncol"},{"key":"5600_CR5","first-page":"38","volume":"4","author":"AS Pasciak","year":"2014","unstructured":"Pasciak AS, et al. Radioembolization and the dynamic role of (90)Y PET\/CT. Front Oncol. 2014;4:38.","journal-title":"Front Oncol"},{"issue":"7","key":"5600_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/bjs.1800790744","volume":"79","author":"WY Lau","year":"1992","unstructured":"Lau WY, Li AK. Therapeutic aspects of radioisotopes in hepatobiliary malignancy. Br J Surg. 1992;79(7):711.","journal-title":"Br J Surg"},{"issue":"4","key":"5600_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","volume":"56","author":"K Okuda","year":"1985","unstructured":"Okuda K, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918\u201328.","journal-title":"Cancer"},{"issue":"9160","key":"5600_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(98)09148-X","volume":"353","author":"DF Schafer","year":"1999","unstructured":"Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353(9160):1253\u20137.","journal-title":"Lancet"},{"issue":"12","key":"5600_CR9","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1007\/s00259-010-1566-2","volume":"37","author":"B Lambert","year":"2010","unstructured":"Lambert B, et al. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37(12):2328\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5600_CR10","first-page":"70","volume":"35","author":"WT Leung","year":"1994","unstructured":"Leung WT, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70\u20133.","journal-title":"J Nucl Med"},{"issue":"3","key":"5600_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00330-017-4998-2","volume":"28","author":"A Braat","year":"2018","unstructured":"Braat A, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920\u20138.","journal-title":"Eur Radiol"},{"issue":"10","key":"5600_CR12","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00259-014-2784-9","volume":"41","author":"M Elschot","year":"2014","unstructured":"Elschot M, et al. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5600_CR13","first-page":"1673","volume":"41","author":"JE Dancey","year":"2000","unstructured":"Dancey JE, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673\u201381.","journal-title":"J Nucl Med"},{"issue":"5 Suppl 1","key":"5600_CR14","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1053\/j.gastro.2004.09.034","volume":"127","author":"JF Geschwind","year":"2004","unstructured":"Geschwind JF, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194\u2013205.","journal-title":"Gastroenterology"},{"issue":"2 Pt 1","key":"5600_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.RVI.0000142602.79459.90","volume":"16","author":"JE Goin","year":"2005","unstructured":"Goin JE, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195\u2013203.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"5600_CR16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","volume":"60","author":"AS Kennedy","year":"2004","unstructured":"Kennedy AS, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5600_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0360-3016(97)00818-3","volume":"40","author":"WY Lau","year":"1998","unstructured":"Lau WY, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"5600_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2006.08.7916","volume":"25","author":"RA Sharma","year":"2007","unstructured":"Sharma RA, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099\u2013106.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5600_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1091-255X(01)80051-2","volume":"5","author":"RS Stubbs","year":"2001","unstructured":"Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294\u2013302.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"5600_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40658-015-0113-4","volume":"2","author":"J Hogberg","year":"2015","unstructured":"Hogberg J, et al. Increased absorbed liver dose in selective internal radiation therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys. 2015;2(1):10.","journal-title":"EJNMMI Phys"},{"issue":"2 Suppl 1","key":"5600_CR21","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1002\/lt.20036","volume":"10","author":"BI Carr","year":"2004","unstructured":"Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107\u201310.","journal-title":"Liver Transpl"},{"issue":"3","key":"5600_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-009-1279-6","volume":"37","author":"E Garin","year":"2010","unstructured":"Garin E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5600_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ijrobp.2006.05.065","volume":"66","author":"B Sangro","year":"2006","unstructured":"Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):792\u2013800.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5600_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jso.20141","volume":"88","author":"G Van Hazel","year":"2004","unstructured":"Van Hazel G, et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil\/leucovorin chemotherapy versus fluorouracil\/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78\u201385.","journal-title":"J Surg Oncol"},{"issue":"2","key":"5600_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijrobp.2013.05.041","volume":"87","author":"MG Lam","year":"2013","unstructured":"Lam MG, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(2):323\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"5600_CR26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jvir.2007.07.016","volume":"18","author":"JY Young","year":"2007","unstructured":"Young JY, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375\u201382.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"5600_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","volume":"53","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, et al. 90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"5600_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","volume":"43","author":"A Braat","year":"2020","unstructured":"Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy. Cardiovasc Intervent Radiol. 2020;43(2):246\u201353.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"5600_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/cncr.23339","volume":"112","author":"B Sangro","year":"2008","unstructured":"Sangro B, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538\u201346.","journal-title":"Cancer"},{"issue":"15","key":"5600_CR30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA van Hazel","year":"2016","unstructured":"van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723\u201331.","journal-title":"J Clin Oncol"},{"key":"5600_CR31","doi-asserted-by":"crossref","unstructured":"Mulcahy, M.F., et al., Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol, 2021: p. JCO2101839.","DOI":"10.1016\/j.annonc.2021.08.2095"},{"issue":"9","key":"5600_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159\u201371.","journal-title":"Lancet Oncol"},{"issue":"6","key":"5600_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164\u201374.","journal-title":"J Hepatol"},{"key":"5600_CR34","volume-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","author":"J Edeline","year":"2019","unstructured":"Edeline, J., et al., Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol, 2019."},{"issue":"6","key":"5600_CR35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.ejrad.2016.03.029","volume":"85","author":"W Shady","year":"2016","unstructured":"Shady W, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET\/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85(6):1224\u201331.","journal-title":"Eur J Radiol"},{"issue":"3","key":"5600_CR36","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2214\/AJR.15.15202","volume":"207","author":"W Shady","year":"2016","unstructured":"Shady W, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol. 2016;207(3):661\u201370.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"5600_CR37","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2967\/jnumed.112.116426","volume":"54","author":"WP Fendler","year":"2013","unstructured":"Fendler WP, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202\u20138.","journal-title":"J Nucl Med"},{"issue":"7","key":"5600_CR38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-011-1758-4","volume":"38","author":"SA Gulec","year":"2011","unstructured":"Gulec SA, et al. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38(7):1289\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5600_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/MNM.0b013e32835f9427","volume":"34","author":"C Soydal","year":"2013","unstructured":"Soydal C, et al. The prognostic value of quantitative parameters of 18F-FDG PET\/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34(5):501\u20136.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"5600_CR40","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00259-012-2149-1","volume":"39","author":"I Zerizer","year":"2012","unstructured":"Zerizer I, et al. The role of early (1)(8)F-FDG PET\/CT in prediction of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39(9):1391\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5600_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13550-016-0248-x","volume":"7","author":"M Braat","year":"2017","unstructured":"Braat M, et al. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res. 2017;7(1):2.","journal-title":"EJNMMI Res"},{"issue":"12","key":"5600_CR42","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"key":"5600_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/1471-2407-14-497","volume":"14","author":"SJ Dutton","year":"2014","unstructured":"Dutton SJ, et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.","journal-title":"BMC Cancer"},{"issue":"12","key":"5600_CR44","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1023\/A:1013569329846","volume":"12","author":"B Gray","year":"2001","unstructured":"Gray B, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711\u201320.","journal-title":"Ann Oncol"},{"issue":"19","key":"5600_CR45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5600_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"5600_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1159\/000510798","volume":"9","author":"K Schutte","year":"2020","unstructured":"Schutte K, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9(6):771\u201386.","journal-title":"Liver Cancer"},{"key":"5600_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9010056","volume":"9","author":"M Kohler","year":"2019","unstructured":"Kohler M, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization. J Clin Med. 2019;9:1.","journal-title":"J Clin Med"},{"issue":"1","key":"5600_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejpb.2005.06.005","volume":"62","author":"AP Hunt","year":"2006","unstructured":"Hunt AP, et al. Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging. Eur J Pharm Biopharm. 2006;62(1):26\u201331.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"5600_CR50","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00259-019-04617-9","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, Maccauro M. (166)Ho microsphere scout dose for more accurate radioembolization treatment planning. Eur J Nucl Med Mol Imaging. 2020;47(4):744\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"5600_CR51","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2967\/jnumed.115.169987","volume":"57","author":"OS Grosser","year":"2016","unstructured":"Grosser OS, et al. Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-microspheres used in preradioembolization dosimetry: influence on the liver-lung shunt. J Nucl Med. 2016;57(6):925\u20137.","journal-title":"J Nucl Med"},{"issue":"9","key":"5600_CR52","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1002\/mp.13575","volume":"46","author":"B Lopez","year":"2019","unstructured":"Lopez B, et al. Calculation of lung mean dose and quantification of error for (90) Y-microsphere radioembolization using (99m) Tc-MAA SPECT\/CT and diagnostic chest CT. Med Phys. 2019;46(9):3929\u201340.","journal-title":"Med Phys"},{"issue":"4","key":"5600_CR53","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00259-019-04517-y","volume":"47","author":"A Das","year":"2020","unstructured":"Das A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020;47(4):807\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5600_CR54","first-page":"293","volume":"24","author":"S Ho","year":"1997","unstructured":"Ho S, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293\u20138.","journal-title":"Eur J Nucl Med"},{"issue":"5","key":"5600_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/COC.0b013e318168ef65","volume":"31","author":"R Salem","year":"2008","unstructured":"Salem R, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"5600_CR56","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00259-019-04465-7","volume":"47","author":"A Jadoul","year":"2020","unstructured":"Jadoul A, et al. Comparative dosimetry between (99m)Tc-MAA SPECT\/CT and (90)Y PET\/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):828\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"5600_CR57","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2967\/jnumed.116.173104","volume":"57","author":"S Gnesin","year":"2016","unstructured":"Gnesin S, et al. Partition model based Tc-99m-MAA SPECT\/CT predictive dosimetry compared with Y-90 TOF PET\/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672\u20138.","journal-title":"J Nucl Med"},{"issue":"11","key":"5600_CR58","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.2967\/jnumed.115.162685","volume":"56","author":"H Ilhan","year":"2015","unstructured":"Ilhan H, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654\u201360.","journal-title":"J Nucl Med"},{"issue":"8","key":"5600_CR59","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","volume":"54","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294\u2013301.","journal-title":"J Nucl Med"},{"issue":"5","key":"5600_CR60","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"P Haste","year":"2017","unstructured":"Haste P, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission ct and posttreatment positron emission tomography\/CT. J Vasc Interv Radiol. 2017;28(5):722\u201330.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"5600_CR61","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","volume":"40","author":"E Garin","year":"2013","unstructured":"Garin E, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5600_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.111.094235","volume":"53","author":"E Garin","year":"2012","unstructured":"Garin E, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255\u201363.","journal-title":"J Nucl Med"},{"issue":"2","key":"5600_CR63","first-page":"168","volume":"55","author":"C Chiesa","year":"2011","unstructured":"Chiesa C, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55(2):168\u201397.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"12","key":"5600_CR64","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-018-4064-6","volume":"45","author":"CL Ho","year":"2018","unstructured":"Ho CL, et al. Radioembolization with (90)Y glass microspheres for hepatocellular carcinoma: significance of pretreatment (11)C-acetate and (18)F-FDG PET\/CT and posttreatment (90)Y PET\/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018;45(12):2110\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5600_CR65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"AL Hermann","year":"2020","unstructured":"Hermann AL, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673\u201384.","journal-title":"Radiology"},{"issue":"5","key":"5600_CR66","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bjc.1994.436","volume":"70","author":"WY Lau","year":"1994","unstructured":"Lau WY, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70(5):994\u20139.","journal-title":"Br J Cancer"},{"key":"5600_CR67","unstructured":"Garin, E., et al., Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol, 2020"},{"issue":"4","key":"5600_CR68","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","volume":"47","author":"MLJ Smits","year":"2020","unstructured":"Smits MLJ, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798\u2013806.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"5600_CR69","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46(8):1695\u2013704.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5600_CR70","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050\u20138.","journal-title":"Radiology"},{"issue":"2","key":"5600_CR71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.21037\/jgo.2017.11.02","volume":"9","author":"C Meiers","year":"2018","unstructured":"Meiers C, et al. Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases. J Gastrointest Oncol. 2018;9(2):311\u20135.","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"5600_CR72","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jvir.2014.03.030","volume":"25","author":"SA Padia","year":"2014","unstructured":"Padia SA, et al. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067\u201373.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"5600_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","volume":"29","author":"DM Biederman","year":"2018","unstructured":"Biederman DM, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30\u20137 e2.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"5600_CR74","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2967\/jnumed.114.145177","volume":"56","author":"E Garin","year":"2015","unstructured":"Garin E, et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56(3):339\u201346.","journal-title":"J Nucl Med"},{"key":"5600_CR75","doi-asserted-by":"crossref","unstructured":"Konijnenberg M., et al. EANM position paper on article 56 of the Council Directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021:48(1);67\u201372","DOI":"10.1007\/s00259-020-05038-9"},{"key":"5600_CR76","doi-asserted-by":"crossref","unstructured":"Ho S, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23(8):947\u201352","DOI":"10.1007\/BF01084369"},{"issue":"11","key":"5600_CR77","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s00259-015-3068-8","volume":"42","author":"C Chiesa","year":"2015","unstructured":"Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"5600_CR78","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1002\/mp.13851","volume":"46","author":"C Chiesa","year":"2019","unstructured":"Chiesa C, Bardies M, Zaidi H. Voxel-based dosimetry is superior to mean absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy. Med Phys. 2019;46(12):5403\u20136.","journal-title":"Med Phys"},{"issue":"1","key":"5600_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2967\/jnumed.119.226472","volume":"61","author":"YK Dewaraja","year":"2020","unstructured":"Dewaraja YK, et al. Prediction of tumor control in (90)Y radioembolization by logit models with PET\/CT-based dose metrics. J Nucl Med. 2020;61(1):104\u201311.","journal-title":"J Nucl Med"},{"issue":"2","key":"5600_CR80","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ijrobp.2018.05.062","volume":"102","author":"SC Kappadath","year":"2018","unstructured":"Kappadath SC, et al. Hepatocellular carcinoma tumor dose response after (90)Y-radioembolization with glass microspheres using (90)Y-SPECT\/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5600_CR81","doi-asserted-by":"crossref","unstructured":"Chiesa, C., et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre- and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021:8(1);77","DOI":"10.1186\/s40658-021-00394-3"},{"key":"5600_CR82","doi-asserted-by":"crossref","unstructured":"Roosen, J., et al., To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging, 2021.","DOI":"10.1007\/s00259-021-05340-0"},{"key":"5600_CR83","doi-asserted-by":"crossref","unstructured":"Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology. 2021.","DOI":"10.1002\/hep.31819"},{"issue":"1","key":"5600_CR84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jso.24269","volume":"114","author":"RJ Lewandowski","year":"2016","unstructured":"Lewandowski RJ, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99\u2013105.","journal-title":"J Surg Oncol"},{"issue":"3","key":"5600_CR85","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00259-017-3845-7","volume":"45","author":"X Palard","year":"2018","unstructured":"Palard X, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392\u2013401.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"5600_CR86","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5600_CR87","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/1097-0142(19921101)70:9<2250::AID-CNCR2820700906>3.0.CO;2-4","volume":"70","author":"FA Shepherd","year":"1992","unstructured":"Shepherd FA, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250\u20134.","journal-title":"Cancer"},{"issue":"3","key":"5600_CR88","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00259-018-4199-5","volume":"46","author":"H Bourien","year":"2019","unstructured":"Bourien H, et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging. 2019;46(3):669\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"5600_CR89","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","volume":"24","author":"S Mouli","year":"2013","unstructured":"Mouli S, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227\u201334.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"5600_CR90","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.26223","volume":"123","author":"SA Padia","year":"2021","unstructured":"Padia SA, et al. Yttrium-90 radiation segmentectomy for hepatic metastases: a multi-institutional study of safety and efficacy. J Surg Oncol. 2021;123(1):172\u20138.","journal-title":"J Surg Oncol"},{"key":"5600_CR91","doi-asserted-by":"crossref","unstructured":"Alsultan, A.A., et al., Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases. J Nucl Med, 2021.","DOI":"10.2967\/jnumed.120.255745"},{"issue":"10","key":"5600_CR92","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00259-014-2799-2","volume":"41","author":"RJ Lewandowski","year":"2014","unstructured":"Lewandowski RJ, et al. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1861\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5600_CR93","doi-asserted-by":"crossref","unstructured":"Levillain, H., et al., International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging, 2021","DOI":"10.1007\/s00259-020-05163-5"},{"issue":"11","key":"5600_CR94","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","volume":"46","author":"H Levillain","year":"2019","unstructured":"Levillain H, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2019;46(11):2270\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"5600_CR95","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.115.166942","volume":"57","author":"AF van den Hoven","year":"2016","unstructured":"van den Hoven AF, et al. Insights into the dose-response relationship of radioembolization with resin 90y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"5600_CR96","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2967\/jnumed.119.232751","volume":"61","author":"R Bastiaannet","year":"2020","unstructured":"Bastiaannet R, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608\u201312.","journal-title":"J Nucl Med"},{"issue":"2","key":"5600_CR97","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2967\/jnumed.120.243832","volume":"62","author":"C van Roekel","year":"2021","unstructured":"van Roekel C, et al. Dose-effect relationships of (166)Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272\u20139.","journal-title":"J Nucl Med"},{"issue":"3","key":"5600_CR98","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/jlts.2002.31654","volume":"8","author":"JN Vauthey","year":"2002","unstructured":"Vauthey JN, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233\u201340.","journal-title":"Liver Transpl"},{"issue":"1","key":"5600_CR99","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13550-015-0133-z","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(1):54.","journal-title":"EJNMMI Res"},{"issue":"7","key":"5600_CR100","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","volume":"38","author":"F Giammarile","year":"2011","unstructured":"Giammarile F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393\u2013406.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5600_CR101","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s00259-010-1470-9","volume":"37","author":"R Lhommel","year":"2010","unstructured":"Lhommel R, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37(9):1654\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5600_CR102","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.apradiso.2006.08.009","volume":"65","author":"RG Selwyn","year":"2007","unstructured":"Selwyn RG, et al. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot. 2007;65(3):318\u201327.","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"5600_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12880-020-00452-9","volume":"20","author":"S Kesim","year":"2020","unstructured":"Kesim S, et al. Unexpected radiation pneumonitis after SIRT with significant decrease in DLCO with internal radiation exposure: a case report. BMC Med Imaging. 2020;20(1):52.","journal-title":"BMC Med Imaging"},{"issue":"23","key":"5600_CR104","doi-asserted-by":"publisher","first-page":"235014","DOI":"10.1088\/1361-6560\/abbc80","volume":"65","author":"L Auditore","year":"2020","unstructured":"Auditore L, et al. Monte Carlo (90)Y PET\/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol. 2020;65(23):235014.","journal-title":"Phys Med Biol"},{"issue":"1","key":"5600_CR105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13550-019-0512-y","volume":"9","author":"NP Scott","year":"2019","unstructured":"Scott NP, McGowan DR. Optimising quantitative (90)Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction. EJNMMI Res. 2019;9(1):40.","journal-title":"EJNMMI Res"},{"issue":"11","key":"5600_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026174","volume":"6","author":"M Elschot","year":"2011","unstructured":"Elschot M, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.","journal-title":"PLoS One"},{"issue":"3","key":"5600_CR107","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00330-012-2648-2","volume":"23","author":"GH van de Maat","year":"2013","unstructured":"van de Maat GH, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23(3):827\u201335.","journal-title":"Eur Radiol"},{"key":"5600_CR108","unstructured":"John, L., Discharge of patients undergoing treatment with radioactive substances, A.R.P.a.N.S. Agency, Editor. 2002: Australia"},{"issue":"12","key":"5600_CR109","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jvir.2014.09.003","volume":"25","author":"JF Prince","year":"2014","unstructured":"Prince JF, et al. Radiation emission from patients treated with holmium-166 radioembolization. J Vasc Interv Radiol. 2014;25(12):1956\u20131963e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"5600_CR110","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00259-015-3277-1","volume":"43","author":"S Laffont","year":"2016","unstructured":"Laffont S, et al. Occupational radiation exposure of medical staff performing (9)(0)Y-loaded microsphere radioembolization. Eur J Nucl Med Mol Imaging. 2016;43(5):824\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5600_CR111","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.radmeas.2013.08.007","volume":"58","author":"J Taleb","year":"2013","unstructured":"Taleb J, et al. Radiation dose measurements for staff members involved in holmium-166 preclinical trial. Radiat Meas. 2013;58:75\u20138.","journal-title":"Radiat Meas"},{"issue":"7","key":"5600_CR112","first-page":"1209","volume":"47","author":"SA Gulec","year":"2006","unstructured":"Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47(7):1209\u201311.","journal-title":"J Nucl Med"},{"issue":"5 Suppl 3","key":"5600_CR113","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1097\/HP.0b013e31826566f0","volume":"103","author":"J Metyko","year":"2012","unstructured":"Metyko J, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management. Health Phys. 2012;103(5 Suppl 3):S204\u20138.","journal-title":"Health Phys"},{"issue":"2","key":"5600_CR114","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/RLU.0000000000002828","volume":"45","author":"M Elsayed","year":"2020","unstructured":"Elsayed M, et al. Incidence of radioembolization-induced liver disease and liver toxicity following repeat 90Y-radioembolization: outcomes at a large tertiary care center. Clin Nucl Med. 2020;45(2):100\u20134.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"5600_CR115","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s00270-013-0547-9","volume":"36","author":"MG Lam","year":"2013","unstructured":"Lam MG, et al. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36(5):1320\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"17","key":"5600_CR116","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.21037\/atm-20-2658","volume":"8","author":"M Masthoff","year":"2020","unstructured":"Masthoff M, et al. Repeated radioembolization in advanced liver cancer. Ann Transl Med. 2020;8(17):1055.","journal-title":"Ann Transl Med"},{"issue":"3","key":"5600_CR117","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2967\/jnumed.113.127662","volume":"55","author":"A Zarva","year":"2014","unstructured":"Zarva A, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360\u20136.","journal-title":"J Nucl Med"},{"issue":"4","key":"5600_CR118","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/annonc\/mds605","volume":"24","author":"HJ Prajapati","year":"2013","unstructured":"Prajapati HJ, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965\u201373.","journal-title":"Ann Oncol"},{"issue":"1","key":"5600_CR119","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"5600_CR120","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.11110282","volume":"262","author":"JH Shim","year":"2012","unstructured":"Shim JH, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262(2):708\u201318.","journal-title":"Radiology"},{"issue":"6","key":"5600_CR121","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","volume":"55","author":"R Gillmore","year":"2011","unstructured":"Gillmore R, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309\u201316.","journal-title":"J Hepatol"},{"key":"5600_CR122","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182\u2013236"},{"issue":"11","key":"5600_CR123","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14737140.2020.1814748","volume":"20","author":"RF Pollock","year":"2020","unstructured":"Pollock RF, et al. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997\u20131009.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"5600_CR124","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00270-018-2148-0","volume":"42","author":"A Braat","year":"2019","unstructured":"Braat A, et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413\u201325.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"5600_CR125","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","volume":"83","author":"K Memon","year":"2012","unstructured":"Memon K, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"5600_CR126","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.ejrad.2016.05.020","volume":"85","author":"L Beuzit","year":"2016","unstructured":"Beuzit L, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85(8):1445\u201352.","journal-title":"Eur J Radiol"},{"issue":"2","key":"5600_CR127","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jvir.2013.10.056","volume":"25","author":"JC Camacho","year":"2014","unstructured":"Camacho JC, et al. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256\u201365.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"5600_CR128","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jso.24141","volume":"113","author":"O Akinwande","year":"2016","unstructured":"Akinwande O, et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443\u20138.","journal-title":"J Surg Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05600-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:09:11Z","timestamp":1650276551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05600-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5600"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05600-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"9 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This guideline summarises the views of the EANM Dosimetry, Oncology and Theranostic, Radiation Protection Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Liability statement"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"M. Weber holds\/held consulting roles for Boston Scientific, Terumo, and Lilly. M. Lam is a consultant and received research support from Terumo and Boston Scientific. UMC Utrecht receives royalty payments from Terumo. C. Chiesa has been a consultant for Boston Scientific and TERUMO for guideline development and congress symposia. He received a research grant in 2018 from Boston Scientific.P. Flamen reports advisory board and consultancy fees for SIRTEX. L. Bodei reports non-remunerated consultant\/speaker roles for AAA-Novartis, ITG, Iba, Clovis Oncology, and MTTI and research grants by AAA-Novartis.E. Garin is a consultant for Boston Scientific (1 grant for DOSISPHERE trial, personal fees). K. Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work.M. Konijnenberg, M. Lustre, M. Cremonesi, S. Gnesin, and T. Kracmerova have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}